Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
This study is currently recruiting participants.
Verified February 2013 by EMD Serono
Sponsor:
EMD Serono
Information provided by (Responsible Party):
EMD Serono
ClinicalTrials.gov Identifier:
NCT01579695
First received: April 12, 2012
Last updated: February 26, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130309095755im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
Condition | Intervention |
---|---|
HIV |
Drug: Tesamorelin for injection |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Prospective |
Official Title: | A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA® |
Resource links provided by NLM:
Further study details as provided by EMD Serono:
Primary Outcome Measures:
- Time to development of malignancies in HIV-infected subjects with abdominal lipohypertrophy exposed to EGRIFTA® vs. concurrent, comparable control group not exposed to EGRIFTA® [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Time to development or worsening of Type 2 Diabetes Mellitus, diabetic retinopathy, hypersensitivity reactions, hepatic and renal function, adverse events and major adverse cardiovascular events [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
Estimated Enrollment: | 3190 |
Study Start Date: | February 2013 |
Estimated Study Completion Date: | January 2025 |
Estimated Primary Completion Date: | December 2024 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Exposed Group will receive Tesamorelin |
Drug: Tesamorelin for injection
Daily 2 mg subcutaneous injections of Tesamorelin
|
Control Group will not receive Tesamorelin |
![](https://webarchive.library.unt.edu/web/20130309095755im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Study Population
Study population will be representative of the HIV-injected population affected by abdominal lipohypertrophy
Criteria
Inclusion Criteria:
All of the following inclusion criteria must be fulfilled:
- Subject has given written informed consent;
- Subject is an adult man or woman ≥ 18 years old;
- Subject has HIV infection;
- Subject has physical evidence of excess abdominal fat, as determined by the examining study physician.
Exclusion Criteria:
Exclusion criteria 1 through 4 are based on the contraindications for EGRIFTA®.
- Disruption of the hypothalamic-pituitary axis, including conditions such as hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma;
- Active malignancy (newly diagnosed or recurrent)
- Known hypersensitivity to tesamorelin and/or mannitol
- Pregnancy or lactation
- Use of EGRIFTA® within 6 months prior to baseline
![](https://webarchive.library.unt.edu/web/20130309095755im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01579695
Contacts
Contact: EMD Serono Medical Information | 888-275-7376 |
Locations
United States, Massachusetts | |
Call EMD Serono Medical Information for information on recruiting sites | Recruiting |
Rockland, Massachusetts, United States, 02370 | |
Call EMD Serono Medical Information for Recruiting Sites | Recruiting |
Rockland, Massachusetts, United States, 02370 |
Sponsors and Collaborators
EMD Serono
Investigators
Study Director: | Alexandra Mangili, MD, MPH | EMD Serono, Inc. |
![](https://webarchive.library.unt.edu/web/20130309095755im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | EMD Serono |
ClinicalTrials.gov Identifier: | NCT01579695 History of Changes |
Other Study ID Numbers: | EMR200147-501 |
Study First Received: | April 12, 2012 |
Last Updated: | February 26, 2013 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by EMD Serono:
HIV with lipohypertrophy |
Additional relevant MeSH terms:
Growth Hormone-Releasing Hormone Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on March 07, 2013